Journal
CLINICAL INFECTIOUS DISEASES
Volume 48, Issue 8, Pages 1096-1101Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/597405
Keywords
-
Categories
Ask authors/readers for more resources
Although bacteriophages have been used for the treatment of patients with bacterial infections in some regions of the world for 19 decades, adequate clinical trials of the safety and efficacy of the treatment have not been reported. The increasing problem of antibiotic resistance has, however, rekindled interest in this approach to therapy. Although potentially significant obstacles to systemic administration of phages exist, topical and oral administration of phages and/or phage products, such as lysins, are feasible in the short term. In addition to exploitation of the effects of native phages and phage products, bioengineering of phages will allow directed specificity and their use as delivery systems for antimicrobial and antivirulence molecules. This brief overview of the history and status of phage therapy, along with speculation about its future, provides a background for understanding of this imminent therapeutic modality.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available